Smallcap Pharma Stock Hits 52-Week High After $20 Million FCCB Fundraising Plan

The positive momentum followed the company’s decision to raise up to $20 million through the issuance of 8% Senior Unsecured Foreign Currency Convertible Bonds (FCCBs) due in 2029. According to the company’s regulatory disclosures, the international fundraising exercise is aimed at supporting future growth initiatives and strengthening its financial position.

Sudarshan Pharma has already allotted FCCBs worth $10 million, with an option to raise an additional $10 million. The bonds are convertible into equity shares at a conversion price of ₹30.19 per share. Upon full conversion, the fundraising could potentially result in the issuance of approximately 6.35 crore equity shares.

Apart from the fundraising move, the company has also been pursuing broader strategic initiatives. It recently proposed migrating its equity shares from the BSE SME platform to the main boards of both BSE and NSE, a move that could enhance liquidity, improve market visibility, and attract a wider base of institutional and retail investors.

The pharma company has reported strong business performance in recent periods. For FY26, consolidated revenue rose over 39% year-on-year to ₹703.06 crore, while net profit increased nearly 56% to ₹23.30 crore. The company also expanded its manufacturing capabilities through the acquisition of an API manufacturing facility.

Sudarshan Pharma operates in the pharmaceutical, specialty chemicals, and active pharmaceutical ingredients (API) segments. The company manufactures APIs, formulations, specialty chemicals, and provides contract manufacturing services to domestic and international customers.

With the stock trading at a record high and investors closely tracking the FCCB fundraising programme, market participants will be watching how effectively the company deploys the fresh capital to drive future growth and strengthen its presence in the pharmaceutical sector.

Disclaimer: This article is for informational purposes only and does not constitute financial advice.